Caris Life Sciences reported total assets of $1229.62M and total liabilities of $637.89M for the quarter ended Jun 2026, up 28.7% year over year. This balance sheet covers 9 quarters of results from Jun 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Current Assets | |||||||||
| Cash & EquivalentsCash & Equiv. | 65.44M | 720.44M | 754.74M | 797.80M | 821.15M | 690.91M | |||
| Short-term InvestmentsInvestments (Current) | 2.20M | 2.25M | 2.27M | 2.29M | 2.31M | 102.20M | |||
| Cash & Current Investments | 67.64M | 722.69M | 757.01M | 800.09M | 823.46M | 793.12M | |||
| Receivables - NetNet Receivables | 88.24M | 50.89M | 26.70M | 112.14M | 90.52M | 116.89M | |||
| Receivables - OtherOther Receivables | 4.60M | 11.20M | 9.90M | 7.20M | 3.70M | 5.90M | |||
| Receivables | 92.84M | 62.09M | 36.60M | 119.34M | 94.22M | 122.79M | |||
| Inventory | 39.57M | 40.61M | 49.30M | 63.62M | 76.29M | 123.79M | |||
| Prepaid Assets | 20.27M | 19.12M | 21.23M | 21.94M | 23.91M | 24.03M | |||
| Current Assets | 215.73M | 833.32M | 854.25M | 997.80M | 1,014.18M | 1,057.83M | |||
| Non-Current Assets | |||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 67.82M | 61.31M | 64.00M | 63.17M | 82.67M | 95.72M | |||
| Goodwill | 19.34M | 19.34M | 19.34M | 19.34M | 19.34M | 19.34M | |||
| Goodwill & Intangibles | 19.34M | 19.34M | 19.34M | 19.34M | 19.34M | 19.34M | |||
| Other Non-Current Assets | 40.84M | 4.09M | 41.08M | 46.98M | 45.35M | 46.20M | 56.73M | ||
| Non-Current Assets | 128.00M | 121.74M | 130.33M | 127.86M | 148.21M | 171.79M | |||
| Assets | 343.73M | 955.06M | 984.57M | 1,125.66M | 1,162.39M | 1,229.62M | |||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payables | 27.79M | 28.73M | 29.00M | 39.21M | 69.80M | 85.99M | |||
| Payables | 27.79M | 28.73M | 29.00M | 39.21M | 69.80M | 85.99M | |||
| Accumulated Expenses | 77.54M | 61.36M | 56.87M | 87.77M | 73.92M | 105.27M | |||
| Short term Debt | 60.09M | 0.10M | 0.16M | 0.17M | 0.17M | 0.18M | |||
| Total Current Liabilities | 165.42M | 90.18M | 86.03M | 127.14M | 143.90M | 191.44M | |||
| Non-Current Liabilities | |||||||||
| Non-Current Debt | 373.14M | 373.61M | 376.30M | 378.82M | 381.40M | 392.97M | |||
| Preferred Stock Liabilities | 2,171.99M | 2,196.65M | 2,221.65M | 2,246.11M | |||||
| Other Non-Current Liabilities | 91.64M | 38.36M | 43.88M | 42.39M | 43.60M | 53.48M | |||
| Total Non-Current Liabilities | 529.28M | 463.79M | 462.33M | 505.97M | 525.30M | 584.41M | |||
| Total Liabilities | 2,359.59M | 2,441.95M | 620.92M | 2,599.86M | 502.15M | 506.21M | 548.36M | 568.90M | 637.89M |
| Shareholder's Equity | |||||||||
| Total Debt | 433.23M | 373.71M | 376.46M | 378.99M | 381.57M | 393.15M | |||
| Common Equity | -2359.59M | -2441.95M | -2498.84M | -2599.86M | 452.90M | 478.36M | 577.31M | 593.49M | 591.73M |
| Liabilities and Shareholders Equity | 343.73M | 955.06M | 984.57M | 1,125.66M | 1,162.39M | 1,229.62M | |||
| Treasury Shares | 734.14M | 734.14M | 734.14M | 734.14M | 1.62M | 1.61M | 1.61M | ||
| Retained Earnings | -2472.30M | 3,123.89M | 3,124.94M | 3,141.72M | 3,158.45M | 3,140.80M |